Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Drug Discov Today. 2018 Apr 7;23(8):1502–1519. doi: 10.1016/j.drudis.2018.04.001

Figure 2.

Figure 2

Proposed workflow for non-tuberculous mycobacteria (NTM) drug discovery. Activities and assays from whole-cell library screening to the preclinical development compound are shown. Light blue boxes indicate NTM-specific assays discussed in more detail in the text. Assay and model gaps are in bold. Gray box indicates generic drug discovery activities and assays described elsewhere [148,149]. Abbreviations: PK, pharmacokinetics; tox, cytotoxicity assays.

HHS Vulnerability Disclosure